RU2018143324A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018143324A3 RU2018143324A3 RU2018143324A RU2018143324A RU2018143324A3 RU 2018143324 A3 RU2018143324 A3 RU 2018143324A3 RU 2018143324 A RU2018143324 A RU 2018143324A RU 2018143324 A RU2018143324 A RU 2018143324A RU 2018143324 A3 RU2018143324 A3 RU 2018143324A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201600397 | 2016-07-04 | ||
DKPA201600397 | 2016-07-04 | ||
DKPA201600612 | 2016-10-11 | ||
DKPA201600612 | 2016-10-11 | ||
DKPA201700236 | 2017-04-04 | ||
DKPA201700236 | 2017-04-04 | ||
PCT/EP2017/066255 WO2018007249A1 (en) | 2016-07-04 | 2017-06-30 | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2018143324A RU2018143324A (ru) | 2020-08-04 |
RU2018143324A3 true RU2018143324A3 (ru) | 2020-08-12 |
RU2759380C2 RU2759380C2 (ru) | 2021-11-12 |
Family
ID=60806291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2018143324A RU2759380C2 (ru) | 2016-07-04 | 2017-06-30 | Применение 1H-пиразоло[4,3-b]пиридинов в качестве ингибиторов PDE1 |
Country Status (38)
Country | Link |
---|---|
US (7) | US10034861B2 (ru) |
EP (2) | EP3478681B1 (ru) |
JP (1) | JP7096171B2 (ru) |
KR (2) | KR102488909B1 (ru) |
CN (1) | CN109311872B (ru) |
AU (1) | AU2017291794C1 (ru) |
CA (1) | CA3026857A1 (ru) |
CL (1) | CL2019000010A1 (ru) |
CO (1) | CO2018013803A2 (ru) |
CR (1) | CR20190003A (ru) |
CY (1) | CY1122957T1 (ru) |
DK (1) | DK3478681T3 (ru) |
DO (1) | DOP2018000266A (ru) |
EC (1) | ECSP18093944A (ru) |
ES (1) | ES2784655T3 (ru) |
GE (1) | GEP20207172B (ru) |
HR (1) | HRP20200440T1 (ru) |
HU (1) | HUE048576T2 (ru) |
IL (1) | IL263511B (ru) |
JO (1) | JO3819B1 (ru) |
LT (1) | LT3478681T (ru) |
MA (1) | MA52593A (ru) |
ME (1) | ME03672B (ru) |
MX (1) | MX2018015734A (ru) |
MY (1) | MY197140A (ru) |
PE (1) | PE20190339A1 (ru) |
PH (1) | PH12018502604A1 (ru) |
PL (1) | PL3478681T3 (ru) |
PT (1) | PT3478681T (ru) |
RS (1) | RS60072B1 (ru) |
RU (1) | RU2759380C2 (ru) |
SG (1) | SG11201810965YA (ru) |
SI (1) | SI3478681T1 (ru) |
SV (1) | SV2018005801A (ru) |
TW (1) | TWI763683B (ru) |
UA (1) | UA122824C2 (ru) |
WO (1) | WO2018007249A1 (ru) |
ZA (1) | ZA201808257B (ru) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
JOP20190126A1 (ar) | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
JP7261801B2 (ja) | 2017-12-14 | 2023-04-20 | ハー・ルンドベック・アクチエゼルスカベット | 1h-ピラゾロ[4,3-b]ピリジンの投与を含む併用治療 |
AR113926A1 (es) * | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
TW201927784A (zh) * | 2017-12-20 | 2019-07-16 | 丹麥商H 朗德貝克公司 | 作為pde1抑制劑之大環 |
CN111511742B (zh) * | 2017-12-20 | 2023-10-27 | H.隆德贝克有限公司 | 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶 |
US10766893B2 (en) | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
EP3982949A4 (en) * | 2019-06-14 | 2023-10-11 | Disarm Therapeutics, Inc. | MRSA1 INHIBITORS |
CN112390750B (zh) * | 2020-11-11 | 2022-03-01 | 常州大学 | 作为选择性磷酸二酯酶2抑制剂的喹啉酮类化合物及其制备方法 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6326379B1 (en) | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
DE19942474A1 (de) | 1999-09-06 | 2001-03-15 | Merck Patent Gmbh | Pyrazolo[4,3-d]pyrimidine |
MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
RU2348633C2 (ru) * | 2002-12-23 | 2009-03-10 | Глаксо Груп Лимитед | ПИРАЗОЛО[3,4-b]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗ |
MXPA06014699A (es) | 2004-07-05 | 2007-03-26 | Astellas Pharma Inc | Derivados de pirazolo-piridina. |
KR100710430B1 (ko) * | 2004-08-24 | 2007-04-24 | 삼성코닝 주식회사 | 면광원 장치 및 이를 갖는 백 라이트 유닛 |
JP2008517060A (ja) | 2004-10-19 | 2008-05-22 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | Crf受容体アンタゴニストおよびその製法 |
JP2008530022A (ja) | 2005-02-04 | 2008-08-07 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 免疫反応調節物質を含む水性ゲル処方物 |
TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
RU2402549C3 (ru) | 2005-04-14 | 2022-03-10 | Оцука Фармасьютикал Ко., Лтд. | Пиперазин-замещенные бензотиофены для лечения психических расстройств |
SI1963280T1 (sl) | 2005-12-22 | 2016-02-29 | Newron Pharmaceuticals S.P.A. | 2-feniletilamino derivati kot modulatorji kalcijevih in/ali natrijevih kanalčkov |
US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
US9006258B2 (en) | 2006-12-05 | 2015-04-14 | Intra-Cellular Therapies, Inc. | Method of treating female sexual dysfunction with a PDE1 inhibitor |
NZ579645A (en) * | 2007-03-14 | 2012-01-12 | Ranbaxy Lab Ltd | Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors |
AU2009322905A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
EP2440234A4 (en) | 2009-06-10 | 2013-11-06 | Univ New York | IMMUNOLOGICAL TARGETING OF PATHOLOGICAL TAU PROTEINS |
ME02352B (me) | 2010-08-12 | 2016-06-20 | Lilly Co Eli | PROTUTIJELA PROTIV N3pGiu-AMILOlDNOG BETA PEPTlDA l NJIHOVA UPOTREBA |
WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
EA034193B1 (ru) | 2011-04-21 | 2020-01-15 | Оригенис Гмбх | Гетероциклические соединения в качестве ингибиторов киназ |
CN104024258B (zh) * | 2011-09-01 | 2017-02-15 | 霍夫曼-拉罗奇有限公司 | 吡咯并吡嗪激酶抑制剂 |
CN104379578B (zh) | 2012-03-19 | 2017-06-09 | 阿比德治疗公司 | 氨基甲酸酯化合物及其制备和使用方法 |
TW201533043A (zh) | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲lrrk2抑制劑的芳基吡咯并吡啶衍生化合物 |
WO2015002754A2 (en) * | 2013-06-21 | 2015-01-08 | Zenith Epigenetics Corp. | Novel bicyclic bromodomain inhibitors |
UA116023C2 (uk) | 2013-07-08 | 2018-01-25 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як антагоністи метаботропного глутаматного рецептора |
US9718818B2 (en) * | 2013-08-22 | 2017-08-01 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
EP3107897A1 (en) | 2014-02-19 | 2016-12-28 | H. Lundbeck A/S | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease |
TWI599358B (zh) | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | 組合療法 |
US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
JP2017527606A (ja) | 2014-09-18 | 2017-09-21 | サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. | 三環系誘導体 |
TW201629064A (zh) | 2014-10-10 | 2016-08-16 | H 朗德貝克公司 | 作爲pde1抑制劑之三唑並吡酮 |
CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
US20180044343A1 (en) | 2015-03-16 | 2018-02-15 | Sumitomo Dainippon Pharma Co., Ltd. | Bicyclic imidazolo derivative |
TW201643167A (zh) | 2015-04-22 | 2016-12-16 | H 朗德貝克公司 | 作爲pde1抑制劑之咪唑並三酮 |
JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
WO2017024004A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
JP2018531889A (ja) | 2015-08-12 | 2018-11-01 | ハー・ルンドベック・アクチエゼルスカベット | Bace1阻害剤としての2−アミノ−3−フルオロ−3−(フルオロメチル)−6−メチル−6−フェニル−3,4,5,6−テトラヒドロピリジン |
WO2017100276A1 (en) | 2015-12-08 | 2017-06-15 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers |
MX2018005767A (es) | 2015-12-09 | 2019-05-16 | Ford Global Tech Llc | Alerta para dispositivo movil olvidado. |
EP3436083A4 (en) | 2016-03-28 | 2019-11-27 | Intra-Cellular Therapies, Inc. | NEW COMPOSITIONS AND METHODS |
US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
JOP20190126A1 (ar) | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
JP7261801B2 (ja) | 2017-12-14 | 2023-04-20 | ハー・ルンドベック・アクチエゼルスカベット | 1h-ピラゾロ[4,3-b]ピリジンの投与を含む併用治療 |
TW201927784A (zh) | 2017-12-20 | 2019-07-16 | 丹麥商H 朗德貝克公司 | 作為pde1抑制劑之大環 |
CN111511742B (zh) | 2017-12-20 | 2023-10-27 | H.隆德贝克有限公司 | 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶 |
US10766893B2 (en) | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
-
2017
- 2017-06-29 US US15/637,920 patent/US10034861B2/en active Active
- 2017-06-30 JP JP2018568885A patent/JP7096171B2/ja active Active
- 2017-06-30 ES ES17734307T patent/ES2784655T3/es active Active
- 2017-06-30 SI SI201730204T patent/SI3478681T1/sl unknown
- 2017-06-30 PL PL17734307T patent/PL3478681T3/pl unknown
- 2017-06-30 MX MX2018015734A patent/MX2018015734A/es active IP Right Grant
- 2017-06-30 WO PCT/EP2017/066255 patent/WO2018007249A1/en active Application Filing
- 2017-06-30 MA MA052593A patent/MA52593A/fr unknown
- 2017-06-30 KR KR1020197000212A patent/KR102488909B1/ko active IP Right Grant
- 2017-06-30 UA UAA201812546A patent/UA122824C2/uk unknown
- 2017-06-30 AU AU2017291794A patent/AU2017291794C1/en active Active
- 2017-06-30 ME MEP-2020-50A patent/ME03672B/me unknown
- 2017-06-30 MY MYPI2018002409A patent/MY197140A/en unknown
- 2017-06-30 KR KR1020227039315A patent/KR102576888B1/ko active IP Right Grant
- 2017-06-30 HU HUE17734307A patent/HUE048576T2/hu unknown
- 2017-06-30 RU RU2018143324A patent/RU2759380C2/ru active
- 2017-06-30 RS RS20200308A patent/RS60072B1/sr unknown
- 2017-06-30 SG SG11201810965YA patent/SG11201810965YA/en unknown
- 2017-06-30 CN CN201780036674.9A patent/CN109311872B/zh active Active
- 2017-06-30 GE GEAP201714955A patent/GEP20207172B/en unknown
- 2017-06-30 LT LTEP17734307.6T patent/LT3478681T/lt unknown
- 2017-06-30 CR CR20190003A patent/CR20190003A/es unknown
- 2017-06-30 EP EP17734307.6A patent/EP3478681B1/en active Active
- 2017-06-30 PT PT177343076T patent/PT3478681T/pt unknown
- 2017-06-30 PE PE2018003262A patent/PE20190339A1/es unknown
- 2017-06-30 EP EP20158664.1A patent/EP3689874A1/en active Pending
- 2017-06-30 CA CA3026857A patent/CA3026857A1/en active Pending
- 2017-06-30 DK DK17734307.6T patent/DK3478681T3/da active
- 2017-07-03 TW TW106122235A patent/TWI763683B/zh active
-
2018
- 2018-07-12 US US16/033,395 patent/US10512632B2/en active Active
- 2018-12-05 IL IL263511A patent/IL263511B/en active IP Right Grant
- 2018-12-05 DO DO2018000266A patent/DOP2018000266A/es unknown
- 2018-12-06 ZA ZA2018/08257A patent/ZA201808257B/en unknown
- 2018-12-09 JO JOP/2018/0116A patent/JO3819B1/ar active
- 2018-12-10 PH PH12018502604A patent/PH12018502604A1/en unknown
- 2018-12-14 SV SV2018005801A patent/SV2018005801A/es unknown
- 2018-12-19 CO CONC2018/0013803A patent/CO2018013803A2/es unknown
- 2018-12-19 EC ECSENADI201893944A patent/ECSP18093944A/es unknown
-
2019
- 2019-01-03 CL CL2019000010A patent/CL2019000010A1/es unknown
- 2019-10-31 US US16/670,408 patent/US10806718B2/en active Active
-
2020
- 2020-03-17 HR HRP20200440TT patent/HRP20200440T1/hr unknown
- 2020-03-20 CY CY20201100264T patent/CY1122957T1/el unknown
- 2020-07-30 US US16/943,496 patent/US11491140B2/en active Active
- 2020-08-21 US US16/999,247 patent/US20200375950A1/en not_active Abandoned
- 2020-10-01 US US17/060,742 patent/US11026923B2/en active Active
- 2020-10-01 US US17/060,796 patent/US11026924B2/en active Active